Synpromics will provide key muscle-selective promoter candidates for the development of new treatment options for Duchenne muscular dystrophy (DMD).
At this year’s Bioprocessing Summit, Dr Graham Whyteside presented on 'Inducible synthetic promoters for the production of gene therapy viral vectors'. Synpromics has developed a novel proprietary inducible expression platform that provides exquisite and tuneable control of gene expression.
The new custom-built centre based at the University of Edinburgh’s allows us to meet increasing global demand for its cutting-edge gene control technology.
Synpromics, the leading synthetic promoter and gene control company, is pleased to announce that it has completed a financing round of £5.2M.
Edinburgh, UK, 16th March 2017 / Synpromics Ltd, the leading synthetic promoter and gene control company, is pleased to announce it has been granted a key patent (EP2668277B1) by the European Patent Office, protecting PromPT™ - its proprietary synthetic promoter development platform.